Johnson Financial Group Inc. lessened its stake in Becton Dickinson and Co (NYSE:BDX) by 37.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 536 shares of the medical instruments supplier’s stock after selling 327 shares during the quarter. Johnson Financial Group Inc.’s holdings in Becton Dickinson and were worth $115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently bought and sold shares of BDX. Legacy Advisors LLC raised its position in shares of Becton Dickinson and by 7,000.0% in the 4th quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares during the last quarter. Amica Retiree Medical Trust raised its position in shares of Becton Dickinson and by 325.0% in the 4th quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 390 shares during the last quarter. FTB Advisors Inc. raised its position in shares of Becton Dickinson and by 114.2% in the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares during the last quarter. Penserra Capital Management LLC purchased a new position in shares of Becton Dickinson and in the 4th quarter worth about $136,000. Finally, Exane Derivatives raised its position in shares of Becton Dickinson and by 848.6% in the 4th quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 628 shares during the last quarter. 77.50% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Timothy M. Ring sold 269,661 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the completion of the sale, the director now owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.00% of the stock is owned by corporate insiders.
A number of equities analysts have weighed in on BDX shares. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 target price for the company in a research report on Wednesday, January 3rd. Deutsche Bank set a $260.00 target price on Becton Dickinson and and gave the stock a “buy” rating in a research report on Friday, December 29th. Argus boosted their target price on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research report on Friday, November 3rd. Finally, Bank of America reissued a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson and in a research report on Friday, January 19th. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and presently has an average rating of “Buy” and a consensus target price of $237.27.
Shares of Becton Dickinson and Co (NYSE BDX) opened at $220.34 on Friday. Becton Dickinson and Co has a 52-week low of $175.66 and a 52-week high of $248.39. The company has a market cap of $58,660.00, a PE ratio of 88.49, a PEG ratio of 1.56 and a beta of 1.12. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the firm earned $2.33 EPS. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. sell-side analysts expect that Becton Dickinson and Co will post 10.94 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.36%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s payout ratio is currently 120.48%.
ILLEGAL ACTIVITY WARNING: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/24/becton-dickinson-and-co-bdx-stake-lessened-by-johnson-financial-group-inc.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.